Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
22.21
+0.79 (3.69%)
Apr 2, 2026, 2:45 PM EDT - Market open
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 19 analysts that cover Ultragenyx Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $59.32, which forecasts a 167.09% increase in the stock price over the next year. The lowest target is $25 and the highest is $105.
Price Target: $59.32 (+167.09%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 8 | 8 | 7 |
| Buy | 8 | 8 | 11 | 11 | 11 | 10 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 19 | 20 | 20 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $61 → $25 | Strong Buy → Hold | Downgrades | $61 → $25 | +12.56% | Mar 24, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $120 → $74 | Buy | Maintains | $120 → $74 | +233.18% | Mar 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $128 → $79 | Strong Buy | Maintains | $128 → $79 | +255.70% | Feb 18, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $37 → $34 | Buy | Maintains | $37 → $34 | +53.08% | Feb 18, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $39 → $37 | Buy | Maintains | $39 → $37 | +66.59% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
761.28M
from 673.00M
Increased by 13.12%
Revenue Next Year
1.08B
from 761.28M
Increased by 42.13%
EPS This Year
-4.44
from -5.83
EPS Next Year
-0.77
from -4.44
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 863.1M | 1.7B | |||
| Avg | 761.3M | 1.1B | |||
| Low | 597.5M | 858.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.2% | 125.8% | |||
| Avg | 13.1% | 42.1% | |||
| Low | -11.2% | 12.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.10 | 1.92 | |||
| Avg | -4.44 | -0.77 | |||
| Low | -5.50 | -2.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.